Sigilon Therapeutics Stock Fundamentals

SGTXDelisted Stock  USD 21.11  0.33  1.54%   
Sigilon Therapeutics fundamentals help investors to digest information that contributes to Sigilon Therapeutics' financial success or failures. It also enables traders to predict the movement of Sigilon Stock. The fundamental analysis module provides a way to measure Sigilon Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Sigilon Therapeutics stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Sigilon Therapeutics Company Return On Equity Analysis

Sigilon Therapeutics' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.

Return On Equity

 = 

Net Income

Total Equity

More About Return On Equity | All Equity Analysis

Current Sigilon Therapeutics Return On Equity

    
  -0.76  
Most of Sigilon Therapeutics' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sigilon Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Competition

Based on the latest financial disclosure, Sigilon Therapeutics has a Return On Equity of -0.7631. This is 96.82% lower than that of the Biotechnology sector and 97.91% lower than that of the Health Care industry. The return on equity for all United States stocks is 146.16% higher than that of the company.

Sigilon Therapeutics Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Sigilon Therapeutics's current stock value. Our valuation model uses many indicators to compare Sigilon Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Sigilon Therapeutics competition to find correlations between indicators driving Sigilon Therapeutics's intrinsic value. More Info.
Sigilon Therapeutics is rated fourth in return on equity category among its peers. It is currently regarded as top stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Sigilon Therapeutics' earnings, one of the primary drivers of an investment's value.

Sigilon Return On Equity Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sigilon Therapeutics' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Sigilon Therapeutics could also be used in its relative valuation, which is a method of valuing Sigilon Therapeutics by comparing valuation metrics of similar companies.
Sigilon Therapeutics is currently under evaluation in return on equity category among its peers.

Sigilon Fundamentals

About Sigilon Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Sigilon Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sigilon Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sigilon Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Sigilon Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. Sigilon Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 66 people.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.

Other Consideration for investing in Sigilon Stock

If you are still planning to invest in Sigilon Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Sigilon Therapeutics' history and understand the potential risks before investing.
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world